BiotechTube
Pumpinheart

Pumpinheart

Dublin, Ireland· Est.
pumpinheart.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pumpinheart is a private, pre-revenue Irish medtech startup targeting the significant unmet need in HFpEF, a prevalent and difficult-to-treat form of heart failure. Its core innovation is the PReduction device, an ECG-gated, transcatheter-implanted pump system powered by a transcutaneous energy transfer system (TETS), currently in the preclinical research phase. The company has garnered notable grant funding, including a €3.14M Disruptive Technologies Innovation Fund award, and has won several startup and innovation awards, positioning it for continued development toward first-in-human trials.

Cardiovascular

Technology Platform

The PReduction device platform is an ECG-gated, transcatheter-implantable diastolic pump system for the left ventricle, integrated with a subcutaneous control unit and a Transcutaneous Energy Transfer System (TETS) for wireless power, designed to reduce left atrial pressure in HFpEF patients.

Opportunities

The primary opportunity is addressing the vast, unmet need in HFpEF, a multi-billion dollar market with no approved device therapies.
Successful development could position Pumpinheart as a first-mover, leading to a strategic acquisition or partnership with a major cardiac device company.
The transcatheter delivery and TETS system offer potential advantages in patient quality of life and reduced infection risk compared to surgical options.

Risk Factors

Major risks include the high technical and clinical uncertainty of a novel, first-in-class device mechanism, requiring a long (7+ year) and costly development path.
Regulatory hurdles for a chronic cardiovascular implant are significant.
The company faces competition from other entities developing HFpEF solutions and may lack the resources to commercialize independently.

Competitive Landscape

The competitive landscape for HFpEF devices is emerging but not yet crowded with approved products. Pumpinheart competes with other startups and large medtech companies exploring various approaches, including inter-atrial shunts, cardiac contractility modulation, and other forms of mechanical circulatory support. Its unique focus on a diastolic-specific pump differentiates it, but it must prove superior safety and efficacy to succeed in a future competitive market.

More companies in Drug Delivery & Formulation →More companies in Ireland →